|
|
|
| Efficacy of Atorvastatin combined with Dimethylbiguanide in treating elderly type 2 diabetes with dyslipidemia |
| WANG Yonghai1 JIANG Meiju1▲ WANG lin2 ZHOU Hongli1 |
1.Department of Endocrinology, Chengyang People's Hospital, Shandong Province, Qingdao 266109, China;
2.Quality Control Office, Chengyang People's Hospital, Shandong Province, Qingdao 266109, China |
|
|
|
Abstract Objective To investigate effect of Atorvastatin combined with Dimethylbiguanide in treating elderly type 2 diabetes with dyslipidemia. Methods The clinical data of 280 cases of elderly patients diagnosed as type 2 diabetes with dyslipidemia in Chengyang People's Hospital from January 2014 to January 2017 was analyzed, they were divided into two control group (Atorvastatin) and observation group (Atorvastatin combined with Dimethylbiguanide), with 140 cases in each group. The levels of fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated hemoglobin (HbA1c), fasting insulin (Fins), insulin resistance (HOMA-IR), triacylglycerol (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterin (LDL-C) of two groups were detected before and after treatment. The clinical effects of the two groups were observed. Results The levels of FBG, PBG, HbA1c, Fins, HOMA-IR, TG, TC, HDL-C, LDL-C between two groups had no significant differences before treatment (P ＞ 0.05). After treatment, the levels of FBG, PBG, HbA1c, Fins, HOMA-IR, TG, TC, LDL-C in the two groups were all significantly lower than those before treatment, while the levels of HDL-C were higher than those before treatment (P ＜ 0.05). After treatment, the levels of FBG, PBG, HbA1c, Fins, HOMA-IR, TG, TC, LDL-C of observation group were lower than those of control group, while the level of HDL-C was higher than that of control group (P ＜ 0.05). The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P ＜ 0.05). Conclusion Atorvastatin combined with Dimethylbiguanide in treating elderly type 2 diabetes with dyslipidemia can significantly improve the levels of blood glucose and blood lipid, the clinical efficacy is remarkable and it is worthy of promotion and application.
|
|
|
|
|
|
[1] 陈璐菡，潘涛.辛伐他汀联合阿司匹林治疗脑血栓的效果及对神经功能缺损的影响[J].中国医药导报，2016，13（23）：161-164.
[2] Siddiqui FM，Kamal AK. Incidence and epidemiology of cerebral venous thrombosis [J]. J Pak Med Assoc，2006，56（11）：485-487.
[3] 王跃慧，田跃雷，梁文华，等.阿司匹林联合阿托伐他汀对缺血性脑血管病患者血清ox-LDL、炎性因子和颈动脉斑块的影响[J].河北医药，2016，38（11）：1628-1631.
[4] Ruland S，Richardson D，Hung E，et al. Predictors of recurrent stroke in African Americans [J]. Neurology，2006， 67（4）：567-571.
[5] 中华医学会糖尿病学分会.中国２型糖尿病防治指南（2013年版）[J].中华内分泌代谢杂志，2014，30（10）：893-942.
[6] Watts KL，Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor beta is abrogated by simvastatin via a Rho signaling mechanism [J]. Am J Physiol Lung Cell Mol Physiol，2004，287（6）：L1323-L1332.
[7] 陈涛，倪美玲，朱立场，等.瑞舒伐他汀钙与阿托伐他汀钙治疗高脂血症合并高血压的疗效比较[J].中国老年学杂志，2015，24（8）：2017-2019.
[8] World Health Organization. Diabetes mellitus：report of a WHO study group [J]. Geneva：World Health Organization，1985.
[9] 王艳冰.阿托伐他汀钙与辛伐他汀治疗2型糖尿病血脂异常的疗效对比分析[J].转化医学杂志，2015，2（8）：45-46.
[10] Belalcazar LM，Reboussin DM，Haffner M，et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies m etabolic predictors of change：from the Look AH EAD（Action for H ealth in Diabetes）study [J]. Diabetes Care，2010，33（11）：2297.
[11] 胡荣芳，宫立程，吴金义，等.阿托伐他汀钙治疗2型糖尿病合并颈动脉粥样硬化的系统评价[J].中国老年学杂志，2015，35（6）：1515-1517.
[12] Ko GT，Chow CC，Leung G，et al. High rate of increased carotid intima-media thickness and atherosclerotic plagues in Chinese asym ptom atic subjects with central obesity [J]. Int J Cardiovasc Imaging，2011，27（6）：833-841.
[13] 林穗智.阿托伐他汀治疗糖尿病肾病血脂异常的疗效分析[J].中国当代医药，2015，22（16）：129-131.
[14] Thongtang N，Diffenderter MR，Ooi EM，et al. Effects of atorvastatin on human C-reactive protein metabolism [J]. Atherosclerosis，2013，226（2）：466-470.
[15] 黄秋菊，韦秀英，李玉兰，等.血塞通联合阿托伐他汀对合并血脂异常的老年2型糖尿病患者血脂及血清高敏C反应蛋白水平的影响[J].中国老年学杂志，2013， 33（14）：3309-3310.
[16] Adsule SM，Baig MS，Gade PR，et al. A com parative evaluation of safe-ty and efficacy of rosuvastatin，simvastatin，and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia [J]. Int J Diabetes Dev Ctries，2009，29（2）：74-79.
[17] 范国洽，石志平，韩蕊，等.阿托伐他汀降低２型糖尿病大鼠主动脉磷酸化p38丝裂素活化蛋白激酶蛋白的表达[J].中华糖尿病杂志，2014，6（12）：893-897.
[18] 谢义平，罗金琼.二甲双胍治疗2型糖尿病的效果分析[J].中国现代医生，2016，54（21）：114-116.
[19] 刘崇喜.金芪降糖经验汤剂联合二甲双胍对气虚内热证2型糖尿病患者糖脂代谢及血管内皮功能的影响[J].环球中医药，2016，9（6）：737-740.
[20] 陶志敏，王丹萍，张素贞，等.荷丹片对冠心病合并2型糖尿病患者血脂、炎症因子及氧化应激水平的影响[J].中国药房，2017，28（23）：3244-3247.
[21] 张定华，裴文丽，史晓伟，等.糖稳康胶囊治疗2型糖尿病40例[J].西部中医药，2016，29（12）：74-76.
[22] Ismail-Beigi F，Craven T，Banerji MA，et al. Effect of intensive treatment of hyperglyeaemia on mierovascular outcome in type 2 diabetes；all analysis of the ACCORD randomised trail [J]. Lancet，2010，376（9739）：419-430.
[23] Be?覥towski J，Atanassova P，Chaldakov GN，et al. Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat：Role of vitamin D metabolites [J]. Athero Sclerosis，2011，219（2）：526-531.
[24] 舒珍珍，臧淑妃.糖尿病患者血脂紊乱对大血管病变及胰岛素抵抗的影响[J].中国现代医生，2016，54（7）：1-4.
[25] 刘雅凝.加减消渴方联合二甲双胍对气滞血瘀型2型糖尿病相关临床指标的影响[J].世界中医药，2016，11（11）：2271-2273，2277.
[26] 杨鑫，石家振，李新征，等.普罗布考联合二甲双胍对2型糖尿病伴血脂异常患者的疗效评价[J].中国药师，2017， 20（3）：485-488.
[27] 于冬妮，孙明晓，蒋蕾，等.辛伐他汀和血脂康对新发老年2型糖尿病患者的调脂效果和安全性分析[J].中华老年医学杂志，2013，32（3）：267-270.
[28] Reaven GM. Insulin resistance and its consequences：type 2 diabetes mellitus and coronary heart disease In：Leroith D，taylor SI，O lefsky JM，eds Diabetes mellitus：a fundamental and clinical text [J]. Philadelphia：Lippincott Will?鄄iams＆Wiikine，2010，251（7）：604-615.
[29] 李亚娟，顾晓琦，沈小璇，等.胰岛素治疗糖尿病过程中配合山药食疗的效果分析[J].世界中医药，2016，11（12）：2665-2668. |
|
|
|
